Prorelix Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 10.00 K
- Company Age 9 Year, 4 Days
- Last Filing with ROC 31 Mar 2018
- Revenue Growth 67.00%
- Profit Growth 62.65%
- Ebitda 165.77%
- Net Worth 95.76%
- Total Assets 2.17%
About Prorelix Lifesciences
Prorelix Lifesciences Private Limited (PLPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 February 2016 (Nine years 4 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Education Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Avinash Auti and Niranjan Andhalkar serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999PN2016PTC158474
- Company No.
158474
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 2016
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Prorelix Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niranjan Andhalkar  | Director | Current | |
| Avinash Auti | Director | 17-Feb-2016 | Current |
Financial Performance of Prorelix Lifesciences.
Prorelix Lifesciences Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 67% increase. The company also saw a substantial improvement in profitability, with a 62.65% increase in profit. The company's net worth Soared by an impressive increase of 95.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prorelix Lifesciences?
In 2018, Prorelix Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Unique Air Express Biopharma Private LimitedAvinash Auti and Niranjan Andhalkar are mutual person
Prorelix Services LlpNiranjan Andhalkar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prorelix Lifesciences?
Unlock and access historical data on people associated with Prorelix Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prorelix Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prorelix Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.